




SardiniaChem2008

GIORNATA DI STUDIO DEDICATA
ALLA CHIMICA ORGANICA
DELLE MOLECOLE BIOLOGICAMENTE ATTIVE

30 Maggio 2008, Aula Magna della Facoltà di Scienze – Sassari



Comitato Scientifico:

Giampaolo Giacomelli, *Univ. Sassari*; Giovanna Delogu *CNR Sassari*; Salvatore Cabiddu, *Univ. Cagliari*; PierPaolo Piras, *Univ. Cagliari*

Comitato Organizzatore:

Andrea Porcheddu, *Univ. Sassari*; Roberto Dallochio, *CNR Sassari*;
Stefania De Montis *Univ. Cagliari*

Sponsor

hanno contribuito alla realizzazione del convegno:

[UNIVERSITA' di Sassari-Dipartimento di Chimica](#); [UNIVERSITA' di Sassari-Facoltà di Scienze MFN](#); [CNR-Istituto di Chimica Biomolecolare, Sassari](#); [UNIVERSITA' di Cagliari](#);
[SAPIO s.r.l.](#); [SIGMA-ALDRICH s.r.l.](#); [CARLO ERBA Reagenti](#);
[MEDINLAB s.r.l.](#); [VWR International s.r.l.](#)

**SYNTHESIS AND SAR STUDY OF 2-SUBSTITUTED IMIDAZO[2,1-B]
[1,3]BENZOTHAZOLES AND RELATED COMPOUNDS ENDOWED WITH AFFINITY
FOR DOPAMINE D₂ RECEPTORS AS POTENTIAL ANTIPSYCHOTICS**

[Battistina Asproni¹](#), [Jan Kehler²](#), [Sergio Simula¹](#), [Stefania Mura¹](#), [Giovanna Poreu¹](#)

¹Università di Sassari, Dipartimento Farmaco Chimico Tossicologico, Via Muroni 23/a 07100 Sassari;

²H. Lundbeck A/S. Department of Medicinal Chemistry, Ottiliavey 9, DK-2500 Valby, Denmark.


Schizophrenia is a complex disorder affecting approximately 1% of the population. Typical antipsychotic agents such as chlorpromazine and haloperidol block the D₂ subtype of dopamine receptors in a direct relation to their clinical potency. However, although blockade of D₂ receptors improves the positive symptoms of the disease, it also accounts for side effects which strongly limit patient compliance, in particular extrapyramidal effects and hyperprolactinemia.

During the past few years, a second generation of antipsychotic agents has emerged (e.g., clozapine, risperidone, olanzapine, and ziprasidone); they are categorized as atypical in contrast to conventional D₂ blockers and exhibit a dual dopaminergic and serotonergic mechanism of action: a relatively weak dopamine D₂ receptor antagonism in vitro and in vivo, but potentially important activities at other dopaminergic (D₁, D₄) receptors, at serotonergic (5-HT_{1A}, 5HT_{2A}, 5HT₃, 5HT_{2C}), adrenergic (α_1 , α_2), histaminergic (H₁), and muscarinic receptors. They are claimed to be active against both positive and negative symptoms of schizophrenia, even though they do exhibit a variety of other side effects as weight gain, postural hypotension, sedation, dry mouth. For these reasons the search for more effective and less toxic agents still continues [1,2].

In this context we have developed a series of (1,2-diphenyl-imidazolyl)piperazine derivatives (**1**) that are endowed with substantial affinities for both dopamine D₂ receptors as well as 5-HT_{1A} and 5-HT_{2A} serotonin receptors, compound **1a** (R = *o*-OCH₃) of which is representative [3].

We have extended our study on other series of compounds derived from **1** both modifying the 1,2-diphenyl motif attached to the imidazole core, and the phenyl-piperazine moiety.

All novel compounds were submitted by Lundbeck to radioligand binding assay on dopamine, serotonin, adrenergic, histaminergic receptor subtypes. The chemistry and the *in vitro* screening will be discussed in the poster.

**1**

- [1] a) Rowley M.; Bristow L. J.; Hutson P. H. Current and Novel Approaches to the Drug Treatment of Schizophrenia. *J. Med. Chem.* **2001**, *44*, 477-501. b) Marino, M.; J. Knutsen, L. J. S.; Williams M. Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. *J. Med. Chem.* **2008**, *51*, 1077-1107.
- [2] Asproni B.; Pau A.; Bitti M.; Melosu M.; Cerri R.; Dazzi L.; Maciocco E.; Sanna E.; Altomare C.; Trapani G.; Biggio G. Synthesis and Pharmacological Evaluation of 1-[(1,2-Diphenyl-1*H*-4-imidazolyl)methyl]-4-phenylpiperazines with Clozapine-Like Mixed Activities at Dopamine D₂, Serotonin, and GABA_A Receptors. *J. Med. Chem.* **2002**, *45*, 4655-4668.